ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
30
LSK BioPharma announces preliminary review of top-line results from ANGEL study
admin
2019.06.27
29
HLB to merge with US anticancer drug company LSK BioPharma
admin
2019.06.13
28
LSK BIOPHARMA AND JIANGSU HENGRUI MEDICINE ANNOUNCE FDA CLEARANCE TO INITIATE A PHASE 3 CLINICAL TRIAL IN ADVANCED HEPATOCELLUL
admin
27
ASCO-SITC Clinical Immuno-Oncology Symposium 2019 Poster of Rivoceranib AM107 Study
admin
26
LSKB ANNOUNCES THAT THE ANGEL STUDY HAS REACHED ITS PRIMARY COMPLETION DATE
admin
25
LSK BIOPHARMA TO ATTEND AND PRESENT AT THE ASCO 2017 ANNUAL MEETING
admin
24
THE US FDA GRANTS APATINIB ORPHAN DRUG DESIGNATION FOR TREATMENT OF GASTRIC CANCER
admin
23
LSK BIOPHARMA ANNOUNCES STARTING OF SITE INITIATION VISITS IN THE U.S. FOR ITS PHASE 3 GASTRIC CANCER TRIAL STUDYING APATINIB
admin
22
REGULATORY AFFAIRS ASSOCIATE November 9, 2018News JOB DESCRIPTION Responsible for compliance with applicable procedures. This
admin
21
LSKB TO REPORT NON-CLINICAL RIVOCERANIB (APATINIB) COMBINATION WITH IMMUNOTHERAPY
admin
<<
<
11
12
13
14
15